文献速递临床试验与 GCP流行病学与生物统计

在中国男男性行为者中采用梅毒与HIV双重快速自检扩大梅毒检测覆盖率:一项多臂随机对照试验

Expanding syphilis test uptake using rapid dual self-testing for syphilis and HIV among men who have sex with men in China: A multiarm randomized controlled trial.
PubMed 文献 · PLoS Med · 2022-03-02

该开放标签平行三臂随机对照试验于2020年1月7日至7月17日在中国26省124市招募451名男男性行为者,比较标准照护、标准梅毒自检和抽奖激励梅毒自检对梅毒检测率的影响。标准梅毒自检组检测率63.4%、抽奖激励组65.7%,均高于标准照护组14.7%,且每人检测成本更低(26.55、28.09 vs 66.19美元),未报告研究相关不良事件。

要点

  • 标准梅毒自检组检测率63.4% vs 标准照护组14.7%,风险差48.7%(95%CI 37.8%至58.4%,P<0.001)。
  • 抽奖激励梅毒自检组检测率65.7%,与标准自检组相近。
  • 标准自检每人检测成本26.55美元、抽奖激励28.09美元,均低于标准照护66.19美元。

核心结论

  • 与标准照护相比,提供梅毒自检显著提高中国男男性行为者的梅毒检测比例,且每人检测成本更低。

研究设计与样本

  • 开放标签、平行三臂随机对照试验,采用区组大小为12的区组随机化按1:1:1分组。
  • 2020年1月7日至2020年7月17日从中国26省124市招募至少18岁、过去一年与男性发生无套肛交、过去6个月未检测梅毒且有稳定住址和邮寄地址的男性,共入组451人。
  • 三臂分别为标准照护组、标准梅毒自检组和抽奖激励梅毒自检组(检测后有1/10机会赢得15美元),使用梅毒/HIV双重快速检测试剂盒。
  • 主要结局为试验期间经照片验证确认的梅毒检测比例,组间比较采用风险差(RD),按改良意向性分析在至少完成1次随访调查者中进行完整病例分析。

主要发现

  • 最终分析纳入标准照护组136人(90.7%,136/150)、标准梅毒自检组142人(94.0%,142/151)、抽奖激励梅毒自检组137人(91.3%,137/150)。
  • 试验期间至少检测1次梅毒的比例:标准梅毒自检组63.4%(95%CI 55.5%至71.3%,P=0.001),抽奖激励梅毒自检组65.7%(95%CI 57.7%至73.6%,P=0.0002),标准照护组14.7%(95%CI 8.8%至20.7%,P<0.001)。
  • 标准梅毒自检组与标准照护组之间的风险差为48.7%(95%CI 37.8%至58.4%,P<0.001)。
  • 多数自检者(78.5%,95%CI 72.7%至84.4%,P<0.001)报告既往从未检测过梅毒。
  • 每人检测成本:标准梅毒自检组26.55美元,抽奖激励梅毒自检组28.09美元,标准照护组66.19美元;研究期间未报告研究相关不良事件。

临床怎么用

  • 原文结论为:与标准照护相比,提供梅毒自检显著提高中国男男性行为者的梅毒检测比例,且每人检测成本更低。

局限性

  • 原文指出,新型冠状病毒肺炎(COVID-19)限制措施可能放大了对去中心化检测的需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low syphilis testing uptake is a major public health issue among men who have sex with men (MSM) in many low- and middle-income countries. Syphilis self-testing (SST) may complement and extend facility-based testing. We aimed to evaluate the effectiveness and costs of providing SST on increasing syphilis testing uptake among MSM in China. METHODS AND FINDINGS: An open-label, parallel 3-arm randomized controlled trial (RCT) was conducted between January 7, 2020 and July 17, 2020. Men who were at least 18 years of age, had condomless anal sex with men in the past year, reported not testing for syphilis in the last 6 months, and had a stable residence with mailing addresses were recruited from 124 cities in 26 Chinese provinces. Using block randomization with blocks of size 12, enrolled participants were randomly assigned (1:1:1) into 3 arms: standard of care arm, standard SST arm, and lottery incentivized SST arm (1 in 10 chance to win US$15 if they had a syphilis test). The primary outcome was the proportion of participants who tested for syphilis during the trial period and confirmed with photo verification and between arm comparisons were estimated with risk differences (RDs). Analyses were performed on a modified intention-to-treat basis: Participants were included in the complete case analysis if they had initiated at least 1 follow-up survey. The Syphilis/HIV Duo rapid test kit was used. A total of 451 men were enrolled. In total, 136 (90·7%, 136/150) in the standard of care arm, 142 (94·0%, 142/151) in the standard of SST arm, and 137 (91·3%, 137/150) in the lottery incentivized SST arm were included in the final analysis. The proportion of men who had at least 1 syphilis test during the trial period was 63.4% (95% confidence interval [CI]: 55.5% to 71.3%, p = 0.001) in the standard SST arm, 65.7% (95% CI: 57.7% to 73.6%, p = 0.0002) in the lottery incentivized SST arm, and 14.7% (95% CI: 8.8% to 20.7%, p < 0.001) in the standard of care arm. The estimated RD between the standard SST and standard of care arm was 48.7% (95% CI: 37.8% to 58.4%, p < 0.001). The majority (78.5%, 95% CI: 72.7% to 84.4%, p < 0.001) of syphilis self-testers reported never testing for syphilis. The cost per person tested was US$26.55 for standard SST, US$28.09 for the lottery incentivized SST, and US$66.19 for the standard of care. No study-related adverse events were reported during the study duration. Limitation was that the impact of the Coronavirus Disease 2019 (COVID-19) restrictions may have accentuated demand for decentralized testing. CONCLUSIONS: Compared to standard of care, providing SST significantly increased the proportion of MSM testing for syphilis in China and was cheaper (per person tested). TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1900022409.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Wang C, Ong JJ, Zhao P, et al. Expanding syphilis test uptake using rapid dual self-testing for syphilis and HIV among men who have sex with men in China: A multiarm randomized controlled trial. PLoS Med. 2022. PMID: 35235573. doi:10.1371/journal.pmed.1003930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。